Business Wire

SLATE-ASSET-MANAGEMENT

15.9.2022 20:01:38 CEST | Business Wire | Press release

Share
Slate Asset Management Acquires Significant Minority Stake in Roswall Development Inc., a Fully Integrated Canadian Renewable Energy Company

Slate Asset Management (“Slate”), a global alternative investment platform targeting real assets, today announced a strategic partnership with Roswall Development Inc. (“Roswall”), a fully integrated Canadian renewable energy company based in Halifax, Nova Scotia, through the acquisition of a significant minority stake in the company.

Roswall is an experienced developer of renewable energy projects offering complete energy solutions for infrastructure, industries, and communities in partnership with private and public enterprises. Roswall’s full suite of services includes consulting, strategic planning, design-build installations, development, financing, and operations of renewables projects. The leadership team at Roswall has been active in the renewable energy industry for over 15 years, having successfully developed, constructed, and operated C$150 million of wind, solar, and retrofit projects across North America. Roswall was also awarded the first independent retail electricity licence in Nova Scotia in October 2021.

The partnership with Slate will help fund future renewables projects developed by Roswall, which has a significant and actionable pipeline of wind development opportunities that will support its retail operation by providing 100% clean electricity to its customers. Additionally, it has a growing turnkey business focused on commercial, institutional, and industrial markets. The Roswall team will also benefit from the global expertise, resources, and relationships of the broader Slate platform as it looks to scale its platform across Canada and North America.

“We believe that proven and scalable renewable energy solutions can meaningfully improve the resiliency of our cities and communities by reducing energy consumption, minimizing the environmental impacts of energy production, and increasing the reliability and efficiency of our energy sources,” said Christian Schmid, Managing Director and Global Head of Infrastructure at Slate. “Roswall’s experienced team has been on the front lines of the significant energy transition taking place globally over the past decade, working to broaden access to affordable, reliable, sustainable, and modern energy sources across North America. We look forward to partnering closely with the Roswall team on integrations across our own real estate portfolio and supporting their mission of continuing to accelerate the energy transition worldwide.”

Daniel Roscoe, Chief Executive Officer at Roswall, said: “The energy economy is changing at a dramatic pace. We have shown with our work in Nova Scotia and the Caribbean that locally produced renewable energy combined with energy retrofits can provide cost savings, emission reductions, and energy security. We are excited to find a likeminded partner in Slate, with the capacity and experience to grow our approach and accelerate energy transition and climate action here in Nova Scotia and abroad.”

Slate is an active investor in sustainable assets and technologies that advance the global energy transition and enable cities and communities to reach their carbon emission reduction goals. The firm recently hired Jeff Rodgers as Managing Director, North American Infrastructure to support the continued growth of Slate’s infrastructure platform globally, with a focus on uncovering investment opportunities tied to the global energy transition in the US and Canada.

About Slate Asset Management

Slate Asset Management is a global alternative investment platform targeting real assets. We focus on fundamentals with the objective of creating long-term value for our investors and partners. Slate’s platform has a range of real estate and infrastructure investment strategies, including opportunistic, value add, core plus and debt investments. We are supported by exceptional people and flexible capital, which enable us to originate and execute on a wide range of compelling investment opportunities. Visit slateam.com to learn more.

About Roswall Development Inc.

Roswall Development Inc. is an experienced developer of renewable energy projects, encompassing all aspects from financing and construction to operation. We are focused on enabling regions, industries, and public institutions to become energy self-sufficient through development of renewable energy systems and energy efficiency retrofits. Roswall's team has over 15 years of experience with over $150M of wind, solar and retrofit projects successfully developed, constructed and operated. Active in both Canada and the Caribbean, Roswall is helping accelerate the energy transition by helping companies and institutions get to zero emissions cost effectively. Learn more at roswall.ca.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005149/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse

Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release

Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye